Table 1 Patient demographics and clinical characteristics pre- and post-matching

Age, mean (SD)

55.9 (12.0)

56.0 (12.3)

55.9 (12.0)

0.81

55.6 (12.2)

56.0 (12.3)

55.2 (12.2)

0.076

55.4 (12.3)

55.2 (12.0)

55.6 (12.7)

0.57

Quan-Charlson comorbidity score, mean (SD)

0.56 (1.12)

0.78 (1.35)

0.53 (1.07)

<0.001

0.68 (1.23)

0.75 (1.30)

0.61 (1.16)

<0.001

0.64 (1.16)

0.69 (1.22)

0.58 (1.10)

0.063

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

P value ^a

n (%)

n (%)

n (%)

P value ^a

Age

  18-44

2,856 (17.8%)

388 (19.3%)

2,468 (17.6%)

0.07

742 (19.2%)

367 (19.0%)

375 (19.4%)

0.74

348 (19.9)

178 (20.4)

170 (19.7)

0.63

  45-64

9,402 (58.6%)

1,123 (55.7%)

8,279 (59.0%)

0.005

2,196 (56.8%)

1,086 (56.2%)

1,110 (57.5%)

0.44

974 (55.8)

506 (58.0)

468 (53.6)

0.07

  65-74

2,660 (16.6%)

356 (17.7%)

2,304 (16.4%)

0.16

661 (17.1%)

339 (17.6%)

322 (16.7%)

0.47

298 (17.1)

131 (15.0)

167 (19.1)

0.02

  75 and older

1,122 (7.0%)

148 (7.3%)

974 (6.9%)

0.51

265 (6.9%)

140 (7.3%)

125 (6.5%)

0.34

126 (7.2)

58 (6.6)

68 (7.8)

0.36

Gender

  Male

13,607 (84.8%)

1,682 (83.5%)

11,925 (85.0%)

0.07

3,247 (84.0%)

1,610 (83.3%)

1,637 (84.7%)

0.24

1,457 (83.4)

740 (84.8)

717 (82.1)

0.14

  Female

2,433 (15.2%)

333 (16.5%)

2,100 (15.0%)

617 (16.0%)

322 (16.7%)

295 (15.3%)

289 (16.5)

133 (15.2)

156 (17.9)

0.14

Insurance type

0.04

0.33

<0.001

  Commercial

13,429 (83.7%)

1,656 (82.2%)

11,773 (83.9%)

3,203 (82.9%)

1,590 (82.3%)

1,613 (83.5%)

1,433 (82.1)

746 (85.4)

687

Medicare Advantage

2,611 (16.3%)

359 (17.8%)

2,252 (16.1%)

661 (17.1%)

342 (17.7%)

319 (16.5%)

313 (17.9)

127 (14.5)

186

Geographic location

  Northeast

1,168 (7.3%)

137 (6.8%)

1,031 (7.4%)

0.37

280 (7.3%)

132 (6.8%)

148 (7.7%)

0.32

137 (7.8)

74 (8.5)

63 (7.2)

0.33

  Midwest

1,450 (9.0%)

143 (7.1%)

1,307 (9.3%)

0.001

273 (7.1%)

140 (7.3%)

133 (6.9%)

0.66

111 (6.4)

49 (5.6)

62 (7.1)

0.20

  South

11,020 (68.7%)

1,482 (73.6%)

9,538 (68.0%)

<0.001

2,811 (72.8%)

1,415 (73.2%)

1,396 (72.3%)

0.49

1,256 (71.9)

640 (73.3)

616 (70.6)

0.20

  West

2,402 (15.0%)

253 (12.6%)

2,149 (15.3%)

0.001

500 (12.9%)

245 (12.7%)

255 (13.2%)

0.63

242 (13.9)

110 (12.6)

132 (15.1)

0.13

Allopurinol use

5,543 (34.6%)

748 (37.1%)

4,795 (34.2%)

0.010

1,306 (33.8%)

679 (35.1%)

627 (32.5%)

0.08

Comorbidities

Kidney failure

310 (1.9%)

77 (3.8%)

233 (1.7%)

<0.001

126 (3.3%)

61 (3.2%)

65 (3.4%)

0.72

43 (2.5%)

23 (2.6%)

20 (2.3%)

0.64

Heart failure

772 (4.8%)

141 (7.0%)

631 (4.5%)

<0.001

256 (6.6%)

126 (6.5%)

130 (6.7%)

0.80

106 (6.1%)

55 (6.3%)

51 (5.8%)

0.69

Peripheral arterial disease

200 (1.3%)

34 (1.7%)

166 (1.2%)

0.06

65 (1.7%)

30 (1.6%)

35 (1.8%)

0.53

24 (1.4%)

10 (1.1%)

14 (1.6%)

0.64

Osteoarthritis

2,686 (16.8%)

418 (20.7%)

2,268 (16.2%)

<0.001

760 (19.7%)

388 (20.1%)

372 (19.3%)

0.52

325 (18.6%)

155 (17.7%)

170 (19.5%

0.36

Hypertension

9,844 (61.4%)

1,368 (67.9%)

8,476 (60.4%)

<0.001

2,598 (67.2%)

1,297 (67.1%)

1,301 (67.3%)

0.89

1,145 (65.6%)

572 (65.5%)

573 (65.6%)

0.96

Hyperlipidemia

8,857 (55.2%)

1,161 (57.6%)

7,696 (54.9%)

0.021

2,221 (57.5%)

1,114 (57.7%)

1,107 (57.3%)

0.82

984 (56.4%)

489 (56.0%)

495 (56.7%)

0.77

Mean (SD)

Mean (SD)

Mean (SD)

P value

Mean (SD)

Mean (SD)

Mean (SD)

P value

Mean (SD)

Mean (SD)

Mean (SD)

P value

Baseline sUA

8.3 (2.0)

8.4 (2.2)

8.2 (2.0)

0.036

8.3 (2.1)

8.4 (2.2)

8.3 (2.0)

0.97

8.7 (1.8)

8.7 (2.0)

8.7 (1.7)

0.85